Article Text

Download PDFPDF
Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach
  1. Cristina Iftode, MD*,
  2. Giuseppe R. D'Agostino, MD, PhD*,
  3. Angelo Tozzi, MD*,
  4. Tiziana Comito, MD*,
  5. Ciro Franzese, MD*,
  6. Fiorenza De Rose, MD*,
  7. Davide Franceschini, MD*,
  8. Lucia Di Brina, MD*,
  9. Stefano Tomatis, PhD* and
  10. Marta Scorsetti, MD
  1. *Department of Radiotherapy and Radiosurgery, Humanitas Clinical and Research Hospital; and
  2. Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  1. Address correspondence and reprint requests to Cristina Iftode, MD, Department of Radiotherapy and Radiosurgery, Humanitas Clinical and Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy. E-mail: cristina.iftode{at}


Objective Stereotactic body radiation therapy (SBRT) has been successfully used to treat oligometastases of several primary tumors, but few experiences have been described in patients with gynecological oligometastatic cancer, particularly in ovarian neoplasm. The aim of this study was to evaluate the role of this new radiotherapy modality in a series of oligometastatic ovarian cancer patients.

Materials and Methods Clinical records of patients affected by oligometastatic ovarian carcinoma treated with SBRT were reviewed.

Results Twenty-six patients with 44 metastatic lesions (lymph nodes, 63.6%; liver, 31.8%; and lung, 4.5%) treated with SBRT between January 2011 and May 2017 were analyzed. After a median follow-up period of 28.5 months (range, 6–86 months), 17 patients (65.4%) were still alive at time of analysis: 6 are without evidence of disease, 11 experienced a disease progression. Eight patients died of disease, 1 died because of an heart attack while being disease free. The median local control (LC) was not reached. One-, 2-, and 5-year LCs were 92.9%. Median progression-free survival was 19 months, with 1-year progression-free survival of 69.3% and 38% at 2 years, 19% at 5 years. Median overall survival was 64.5 months, with all patients alive after 1 year, 92.7% at 2 years, and 61.7% at 5 years. Five (11.3%) cases experienced G2 toxicity; most common adverse effect was nausea and vomiting (3 cases [6.8%]) followed by abdominal pain (2 cases [4.5%]). None of the patients had grade 3 or grade 4 acute or late toxicity.

Conclusions In conclusion, SBRT is a feasible and safe approach for selected cases of oligometastatic ovarian cancer, with satisfactory results in terms of LC and disease free survival.

  • ovarian cancer
  • oligometastatic
  • stereotactic body radiotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.